胶质母细胞瘤患者的既往恶性肿瘤:2164例患者的一项机构病例研究
该研究利用机构癌症数据管理系统,纳入2007至2014年2164例胶质母细胞瘤(GBM)患者,评估既往癌症(PC)的流行病学及GBM作为第二癌症的分子与临床特征。170例(7.9%)有PC诊断,中位间隔79个月,最常见为乳腺癌(18.8%)和前列腺癌(18.8%)。PC组诊断GBM时年龄更大(66 vs. 59岁,p<0.001),白人比例更高(88.2 vs. 72.8%,p<0.001),更常见EGFR突变(20 vs. 12.3%,p<0.001)或MGMT突变(17.6 vs. 11.6%,p<0.001)。中位生存PC组13个月 vs. 无PC组15个月(p=NS)。多变量分析仅年龄、KPS和诊断年份影响结局。作者认为,尽管分子特征存在差异,两组总体预后和临床病程相似,因此既往恶性肿瘤不应将患者排除在积极治疗或新型研究性治疗之外。
要点
- 7.9%的GBM患者有既往癌症诊断,中位间隔79个月。
- PC组诊断GBM时年龄更大(66 vs. 59岁)且白人比例更高(88.2 vs. 72.8%)。
- PC组更常见EGFR突变(20 vs. 12.3%)或MGMT突变(17.6 vs. 11.6%),但中位生存无显著差异(13 vs. 15个月,p=NS)。
核心结论
- 有既往恶性肿瘤的GBM患者约占GBM患者的8%,尽管分子特征存在显著差异,两组总体预后和临床病程似乎相似。
- 因此,患者诊断GBM前是否有恶性肿瘤不应将其排除在积极治疗或考虑新型研究性治疗之外。
研究设计与样本
- 利用本机构基于网络的癌症数据管理系统,识别2007年至2014年2164例GBM患者。
- 收集基线人口学、分子和临床数据,进行单变量分析比较有和无PC诊断的GBM患者队列,采用Kaplan-Meier和log-rank检验分析生存差异,拟合Cox比例风险模型进行多变量分析。
主要发现
- 170例(7.9%)GBM患者有PC诊断,两次诊断的中位间隔为79个月。
- 最常见的既往癌症病理为乳腺癌(18.8%)和前列腺癌(18.8%)。
- PC组诊断GBM时年龄大于无PC组(66 vs. 59岁,p<0.001),白人比例高于无PC组(88.2 vs. 72.8%,p<0.001)。
- PC组更常见EGFR突变(20 vs. 12.3%,p<0.001)或MGMT突变(17.6 vs. 11.6%,p<0.001)。
- PC组中位生存13个月,无PC组中位生存15个月(p=NS)。
临床怎么用
- 作者认为,患者诊断GBM前是否有恶性肿瘤不应将其排除在积极治疗或考虑新型研究性治疗之外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
More patients are surviving long-term following a cancer diagnosis and as such are at risk for second malignancies. As the most common primary brain tumor, glioblastoma (GBM) will not infrequently occur in this population. No study has examined the incidence of prior cancer (PC) in patients harboring GBM. Here we evaluate the epidemiological features, as well as the molecular and clinical characteristics of GBM as a second cancer. Utilizing a web-based cancer data management system at our institution, we identified 2164 patients harboring GBM from 2007 to 2014. We collected baseline demographic, molecular, and clinical data. Univariate analysis was performed to compare the cohort of GBM patients with and without PC diagnosis. Survival differences were analyzed with Kaplan-Meier and log-rank testing. A Cox-proportional hazards model was fit for multivariable analysis. 170 patients (7.9%) harboring GBM had a PC diagnosis. The median interval between diagnoses was 79 months. The most common pathologies were breast (18.8%) and prostate (18.8%) cancer. Patients with a PC were older at the time of GBM diagnosis than those without PC (66 vs. 59 years, p < 0.001) and were more likely to be white (88.2 vs. 72.8%, p < 0.001). Patients with PC were more likely to harbor an EGFR (20 vs. 12.3%, p < 0.001) or MGMT mutation (17.6 vs. 11.6%, p < 0.001). Median survival was 13 months in the PC cohort and 15 months in the cohort without PC (p = NS). Age, KPS, and diagnosis year were the only factors which influenced outcome in multivariable analysis. Patients who develop GBM following a prior malignancy constitute ~8% of patients with GBM. Despite significant molecular differences these two cohorts appear to have a similar overall prognosis and clinical course. Thus, whether or not a patient harbors a malignancy prior to diagnosis of GBM should not exclude him or her from aggressive treatment or for consideration of novel investigational therapies.
引用
- Zacharia BE, DiStefano N, Mader MM, et al. Prior malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients. J Neurooncol. 2017. PMID: 28551847. doi:10.1007/s11060-017-2512-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。